CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo.

Gray KueberuwaHannah GornallErik Marcelo Alcantar-OrozcoDeborah BouvierZainul Abedin KapaceeRobert Edward HawkinsDavid Edward Gilham

Published in: Journal for immunotherapy of cancer (2017)

CCR7 selection offers a means to enrich T cells of early differentiation status for ACTC. Together our data suggests that these T cells are likely to display enhanced engraftment and persistence in patients in vivo and could therefore improve therapeutic efficacy of ACTC.

Keyphrases

peripheral blood
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
regulatory t cells
prognostic factors
working memory
genome wide
copy number
immune response
patient reported outcomes
deep learning
transcription factor
hematopoietic stem cell